Lytix and Curida: Growth and innovation
Lytix Biopharma and Curida, both Norwegian-owned, have gained attention and acclaim for their innovative approaches and substantial contributions to the healthcare sector.
This author has yet to write their bio.Meanwhile lets just say that we are proud oslocancer contributed a whooping 276 entries.
Lytix Biopharma and Curida, both Norwegian-owned, have gained attention and acclaim for their innovative approaches and substantial contributions to the healthcare sector.
De fire helseklyngene gikk denne uka sammen om et høringsinnspill til Stortinget.
A clinical pilot for personalised risk-based breast cancer screening has been conducted as part of the AnteNOR project. Here are some of the results.
During the breakfast seminar The Future of Cancer Politics four politicians discussed possible health- and cancer policies in their coming party programmes. The seminar was held in Norwegian.